MYLAN is in the news today, with Melbourne's Herald Sun raising concerns that a shortage of its EpiPen product has "left pharmacies in entire country towns and across large sections of cities without the anti-allergy device".
A shipment of the products is expected next week after a month-long shortage which has forced Mylan Australia to ration stocks.
Manufacturing delays in the USA are being blamed for the shortage.
Earlier this year Mylan/Alphapharm initiated a recall of four batches of the 300g EpiPen adrenaline injection syringe auto-injectors due to a potential failure to activate or a need to apply extra force to activate (TD 21 Mar 2017).
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Nov 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Nov 17